GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Societal CDMO Inc (NAS:SCTL) » Definitions » Growth Rank
中文

Societal CDMO (Societal CDMO) Growth Rank : 5 (As of Apr. 24, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Societal CDMO Growth Rank?

Societal CDMO has the Growth Rank of 5.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.


Competitive Comparison of Societal CDMO's Growth Rank

For the Drug Manufacturers - Specialty & Generic subindustry, Societal CDMO's Growth Rank, along with its competitors' market caps and Growth Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Societal CDMO's Growth Rank Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Societal CDMO's Growth Rank distribution charts can be found below:

* The bar in red indicates where Societal CDMO's Growth Rank falls into.



Societal CDMO Growth Rank Related Terms

Thank you for viewing the detailed overview of Societal CDMO's Growth Rank provided by GuruFocus.com. Please click on the following links to see related term pages.


Societal CDMO (Societal CDMO) Business Description

Traded in Other Exchanges
N/A
Address
1 E. Uwchlan Avenue, Suite 112, Exton, PA, USA, 19341
Societal CDMO Inc is a bi-coastal contract development and manufacturing organization. It offers capabilities spanning pre-Investigational New Drug development to commercial manufacturing and packaging for a wide range of therapeutic dosage forms primarily focused on small molecules. The company also provides therapeutic development, end-to-end regulatory support, clinical and commercial manufacturing, aseptic fill/finish, lyophilization, packaging, and logistics services to the global pharmaceutical market.
Executives
Bryan M. Reasons director C/O IMPAX LABORATORIES, INC., 30831 HUNTWOOD AVENUE, HAYWARD CA 94544
Elena Cant director C/O SOCIETAL CDMO, INC., 1 E. UWCHLAN AVENUE, SUITE 112, EXTON PA 19341
Enloe J David Jr director, officer: Chief Executive Officer
James Charles Miller director 490 LAPP ROAD, MALVERN PA 19355
Wayne Weisman director 490 LAPP ROAD, MALVERN PA 19355
William Ashton director C/O HARRISON CONSULTING GROUP, PO BOX 283, NEWTOWN SQUARE PA 19073
Winston J Churchill director C/O SCP PARTNERS, SUITE 300, 1200 LIBERTY RIDGE DRIVE, WAYNE PA 19087
Awm Investment Company, Inc. 10 percent owner 527 MADISON AVENUE, SUITE 2600, NEW YORK NY 10022
Mathew Paul Arens director, 10 percent owner C/O FIRST LIGHT ASSET MANAGEMENT, LLC, 3300 EDINBOROUGH WAY, SUITE 201, EDINA MN 55435
First Light Asset Management, Llc director, 10 percent owner 3300 EDINBOROUGH WAY, SUITE 201, EDINA MN 55435
Laura L. Parks director C/O RECRO PHARMA, INC., 490 LAPP ROAD, MALVERN PA 29355
Michael Berelowitz director 415 EAST 37TH STREET, APT 36C, NEW YORK NY 10016
Ryan David Lake officer: Chief Financial Officer KENSEY NASH CORPORATION, 735 PENNSYLVANIA DRIVE, EXTON PA 19341
Scp Vitalife Partners (israel) Ii, L.p. 10 percent owner SUITE 190, 7 GREAT VALLEY PARKWAY, MALVERN PA 19355
Scp Vitalife Partners Ii Lp 10 percent owner SUITE 190, 7 GREAT VALLEY PARKWAY, MALVERN PA 19355